Recent articles
Here's the Innocent Reason Antero Midstream Shares Got Cut in Half Today
The master limited partnerships of Antero Resources have merged, changed their name, switched to a new operating structure, and kept the same ticker.
Here's Why Natera Rose as Much as 24.7% Today
The genetic testing leader announced full-year 2018 operating results, but the numbers were actually pretty poor.
Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today
The pharma company announced full-year 2018 operating results and reiterated the road map for the year ahead.
Here's My Top Stock to Buy in March
NextEra Energy Partners has a sweet relationship with the nation's largest renewable power generator -- and it pays a 4.4% dividend.
Here's Why FMC Corporation Rose 12.2% in February, Then Collapsed in Early March
The agricultural sciences leader reported full-year 2018 operating results, then abruptly sank in early March.
Here's Why Guardant Health Soared 65.2% in February
The liquid biopsy pioneer has more than doubled since its IPO.
How Albemarle Is Preparing for Next-Generation Lithium-Ion Batteries
Energy storage devices of the next decade will require several times more lithium than what's on the market today.
Here's Why Corcept Therapeutics Shares Rose 11.5% in February
The stock ricocheted around, but ultimately posted a monthly gain.
Here's Why Axovant Gene Therapies Rocketed Higher Today
Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.
Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
Here's Why bluebird bio Gained 16.3% in February
The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.
Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February
Investors cheered the news in a fiscal first-quarter 2019 earnings report.
Here's Why Amarin Gained 17% in February
The stock rose in anticipation of a business update at the end of the month.
3 Stocks to Hold for the Next 20 Years
Looking for stocks you don't have to babysit? Consider these three stocks.
Here's Why ArQule Is Soaring Today
The company reported fourth-quarter and full-year 2018 earnings and guidance for 2019.
3 Takeaways from Puma Biotechnology's 2018 Earnings
The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.
Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today
The gene therapy company saw another peer get gobbled up in an acquisition.
3 Takeaways From Enphase Energy's Q4 2018 Earnings Report
The wait is over for patient shareholders: This solar power system component business is finally profitable.
2 Hot Stocks to Buy in March
A fast-growing pharma and a leader in solar-power hardware have soared in 2019, but they're still buys for investors with a long-term mind-set.
Is ExxonMobil a Buy?
The refining king has been the worst-performing supermajor in the last three years. Can it ride the Permian Basin to a turnaround?